Sleep, Testosterone Therapy and Male Fertility: Behind the Headlines
On October 13, 2026, CNN published a report by urologist Jamin Brahmbhatt on sperm-count trends and male fertility. The report discussed sleep and metabolic health alongside an issue relevant to men considering testosterone replacement therapy: its potential to suppress sperm production.
What research did the CNN report examine?
The CNN report brought together published research and clinical guidance. It did not announce a new treatment trial with a defined treatment period, so the methods need to be read study by study.
The 2022 global analysis combined 223 studies covering more than 57,000 men in 53 countries. It examined trends between 1973 and 2018 among men who had not been selected based on fertility. This was a population-level comparison across decades rather than a test of a sleep program or hormone treatment.
The 2025 review took a narrower approach. It included 58 studies involving 11,787 American men without known infertility and examined samples from 1970 to 2018. The researchers assessed the overall pattern and then adjusted the analysis for region and fertility status.
The sleep finding came from a 2018 study of 1,176 couples. Other evidence included a review of 112 studies on metabolic conditions and an Argentina study of men having routine semen analysis.
The reported details do not establish participants' ages or the sleep study's follow-up length. They therefore provide no separate estimate for men over 45, the audience most relevant to this discussion.
What were the main findings?
Brahmbhatt's CNN report described several different outcomes:
- Long-term global estimates: The 2022 analysis estimated that sperm concentration fell 51.6% and total sperm count fell 62.3% between 1973 and 2018. Those estimates came from the combined international research.
- Different US results: The 2025 review found no overall change in sperm concentration in its initial analysis. After adjustment for region and fertility status, it found a modest annual decline.
- Sleep and pregnancy: In the 2018 study of 1,176 couples, men sleeping under six hours nightly were about 40% less likely to achieve pregnancy with a partner in a given month than men sleeping eight hours.
- Metabolic health: The review of 112 studies linked obesity, diabetes and metabolic syndrome with poorer semen quality and sperm-DNA damage. These findings concerned reproductive measures rather than a tested fertility treatment.
- Heat exposure: The Argentina study associated heat-wave exposure with lower sperm concentration and total sperm count among men having routine semen analysis.
- Testosterone therapy: Brahmbhatt said TRT can suppress sperm production. In some cases, sperm production can fall to zero. He advised discussing fertility-preserving alternatives with a doctor when current or future plans for children matter.
The sleep finding and the TRT warning point to different clinical questions. One concerns a reported link between sleep duration and pregnancy in couples. The other concerns a treatment's effect on sperm production.
For men focused on energy or hormone symptoms, fertility goals may not be the first issue raised. The report makes those goals relevant before a treatment decision. It does not frame fertility as a reason to leave low-testosterone symptoms unaddressed.
Where are the limits of these findings?
The international sperm-count estimates are not a personal fertility forecast. They do not establish that every man's fertility declined over the study period. The US review is also not a simple refutation of the global analysis: its initial result changed after adjustment for region and fertility status.
The sleep result was an association, not proof that short sleep caused the difference in pregnancy chances. It does not establish that prescribing more sleep would produce a specific fertility outcome. The metabolic and heat findings likewise do not establish that any single factor explains the global sperm-count trend.
There are gaps in the reported detail. CNN did not provide an effect size for the links between metabolic conditions and reproductive measures. It also did not give the Argentina study's sample size or quantify the heat-associated changes.
A separate issue is normal variation in semen-analysis results. Brahmbhatt identified abstinence duration and recent illness as relevant factors. Medications and stress can also affect results, alongside collection conditions and laboratory differences. A reference range is not a firm boundary between fertile and infertile.
Brahmbhatt also cautioned against reading an abnormal semen result as a diagnosis of heart disease or diabetes. His account treated it as a reason to review health history and medications, examine the patient and consider other health problems.
Together, these limits call for a focused interpretation: distinguish population trends from personal results, and distinguish measured associations from tested treatments.
Does this change care for men over 45?
The report supports a more complete clinical conversation rather than a new fertility routine. For a man making a personal decision, the useful questions concern fertility goals and how the findings apply to his health history.
How should fertility plans enter a TRT discussion?
Brahmbhatt advises men who want children now or in the future to discuss fertility-preserving alternatives before assuming TRT fits those plans. That discussion belongs with the prescribing clinician. It is a treatment-specific question, not something a global sperm-count headline can answer.
Our guide to fertility planning around testosterone treatment provides related background. The separate question of evaluating low-testosterone concerns also belongs in qualified medical care rather than being settled by a fertility statistic.
How should an abnormal semen result be discussed?
CNN reports that the American Urological Association recommends at least two semen analyses, ideally about a month apart, especially when the first may be abnormal. The European Association of Urology recommends at least two consecutive analyses when the baseline result is abnormal.
These are clinical recommendations for repeat assessment, not a personal testing schedule. The practical point is to discuss interpretation and repeat testing with the clinician evaluating fertility. Medical history and medication review belong in that discussion alongside the laboratory result.
Where do sleep and broader health fit?
The CNN report identifies sleep and stress as relevant parts of the health review. It also discusses metabolic conditions, medications and heat exposure. Sharing prescription and nonprescription medication use can help keep that review complete.
For men concerned about poor sleep or slower recovery, this is a reason to raise those concerns in their own right. It is not necessary to turn them into a fertility explanation before discussing them with a qualified clinician. Fertility questions and broader health concerns can be addressed together without assuming they have one cause.
What this changes: the report reinforces existing guidance on fertility discussions before TRT and clinical interpretation of repeat semen testing rather than establishing a new treatment or changing current best practices.
How Everfitguys helps
Assigning a fertility problem to sleep alone goes beyond the findings, so Everfitguys focuses on measured outcomes and openly stated uncertainty. For men 45 and older concerned about poor sleep, stress or slower recovery, its plain-English reporting helps put hormone claims in context without offering personal medical advice.
Sources
Stay sharp
Get stories
The best writing on craft and life, delivered once a week. No noise, just the good stuff.
